Fidaxomicin (BioDeep_00000249358)

   

natural product


代谢物信息卡片


Fidaxomicin

化学式: C52H74Cl2O18 (1056.4251964)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCc1c(Cl)c(O)c(Cl)c(O)c1C(=O)OC1C(C)OC(OCC2=CC=CCC(O)C(C)=CC(CC)C(OC3OC(C)(C)C(OC(=O)C(C)C)C(O)C3O)C(C)=CC(C)=CCC(C(C)O)OC2=O)C(OC)C1O
InChI: InChI=1S/C52H74Cl2O18/c1-13-30-22-26(6)33(56)18-16-15-17-31(23-66-51-45(65-12)42(61)44(29(9)67-51)69-49(64)35-32(14-2)36(53)39(58)37(54)38(35)57)48(63)68-34(28(8)55)20-19-25(5)21-27(7)43(30)70-50-41(60)40(59)46(52(10,11)72-50)71-47(62)24(3)4/h15-17,19,21-22,24,28-30,33-34,40-46,50-51,55-61H,13-14,18,20,23H2,1-12H3/b16-15+,25-19+,26-22+,27-21+,31-17+/t28-,29-,30+,33+,34?,40-,41+,42+,43+,44-,45+,46+,50-,51-/m1/s1

描述信息

An 18-membered macrolide that is a fermentation product obtained from the Actinomycete Dactylosporangium aurantiacum. A narrow spectrum antibiotic used for treatment of Clostridium difficile-related infections.

同义名列表

1 个代谢物同义名

Fidaxomicin



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

8 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Stuart Johnson, Dale N Gerding, Xue Li, Domenic J Reda, Curtis J Donskey, Kalpana Gupta, Matthew Bidwell Goetz, Michael W Climo, Fred M Gordin, Robert Ringer, Neil Johnson, Michelle Johnson, Lawrence A Calais, Alexa M Goldberg, Ling Ge, Tamara Haegerich. Defining optimal treatment for recurrent Clostridioides difficile infection (OpTION study): A randomized, double-blind comparison of three antibiotic regimens for patients with a first or second recurrence. Contemporary clinical trials. 2022 05; 116(?):106756. doi: 10.1016/j.cct.2022.106756. [PMID: 35398532]
  • Joshua Wolf, Krisztina Kalocsai, Claudia Fortuny, Stefan Lazar, Samantha Bosis, Bartosz Korczowski, Arnaud Petit, Daniel Bradford, Rodney Croos-Dabrera, Elodie Incera, Joost Melis, Rob van Maanen. Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020 12; 71(10):2581-2588. doi: 10.1093/cid/ciz1149. [PMID: 31773143]
  • Md Sorwer Alam Parvez, Md Adnan Karim, Mahmudul Hasan, Jomana Jaman, Ziaul Karim, Tohura Tahsin, Md Nazmul Hasan, Mohammad Jakir Hosen. Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach. International journal of biological macromolecules. 2020 Nov; 163(?):1787-1797. doi: 10.1016/j.ijbiomac.2020.09.098. [PMID: 32950529]
  • Tetsuo Yamaguchi, Hiroe Konishi, Kotaro Aoki, Yoshikazu Ishii, Koji Chono, Kazuhiro Tateda. The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2020 May; 26(5):483-491. doi: 10.1016/j.jiac.2019.12.020. [PMID: 32165071]
  • Krishna Rao, Preeti N Malani. Diagnosis and Treatment of Clostridioides (Clostridium) difficile Infection in Adults in 2020. JAMA. 2020 Apr; 323(14):1403-1404. doi: 10.1001/jama.2019.3849. [PMID: 32150234]
  • Benoit Guery, Areti Georgopali, Andreas Karas, Gbenga Kazeem, Ingrid Michon, Mark H Wilcox, Oliver A Cornely. Pharmacokinetic analysis of an extended-pulsed fidaxomicin regimen for the treatment of Clostridioides (Clostridium) difficile infection in patients aged 60 years and older in the EXTEND randomized controlled trial. The Journal of antimicrobial chemotherapy. 2020 04; 75(4):1014-1018. doi: 10.1093/jac/dkz549. [PMID: 31960058]
  • Anne Mounsey, Kelly Lacy Smith, Vinay C Reddy, Sarah Nickolich. Clostridioides difficile Infection: Update on Management. American family physician. 2020 02; 101(3):168-175. doi: NULL. [PMID: 32003951]
  • Oliver A Cornely, Maria J G T Vehreschild, Nicholas Adomakoh, Areti Georgopali, Andreas Karas, Gbenga Kazeem, Benoit Guery. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2019 Jun; 38(6):1187-1194. doi: 10.1007/s10096-019-03525-y. [PMID: 30911926]
  • Cyrus Jahansouz, Christopher Staley, Scott Kizy, Hongliang Xu, Ann V Hertzel, Jessi Coryell, Stephanie Singroy, Matthew Hamilton, Meri DuRand, David A Bernlohr, Michael J Sadowsky, Alexander Khoruts, Sayeed Ikramuddin. Antibiotic-induced Disruption of Intestinal Microbiota Contributes to Failure of Vertical Sleeve Gastrectomy. Annals of surgery. 2019 06; 269(6):1092-1100. doi: 10.1097/sla.0000000000002729. [PMID: 31082907]
  • Mayur S Ramesh, Jerry Yee. Clostridioides difficile Infection in Chronic Kidney Disease/End-Stage Renal Disease. Advances in chronic kidney disease. 2019 01; 26(1):30-34. doi: 10.1053/j.ackd.2019.01.001. [PMID: 30876614]
  • Christoph Högenauer, Yashwant Mahida, Andreas Stallmach, Philippe Marteau, Grazyna Rydzewska, Vladimir Ivashkin, Panagiotis Gargalianos-Kakolyris, Ingrid Michon, Nicholas Adomakoh, Areti Georgopali, Reiner Tretter, Andreas Karas, Walter Reinisch. Pharmacokinetics and safety of fidaxomicin in patients with inflammatory bowel disease and Clostridium difficile infection: an open-label Phase IIIb/IV study (PROFILE). The Journal of antimicrobial chemotherapy. 2018 12; 73(12):3430-3441. doi: 10.1093/jac/dky368. [PMID: 30260412]
  • Molly A O'Gorman, Marian G Michaels, Sheldon L Kaplan, Anthony Otley, Larry K Kociolek, Edward J Hoffenberg, Kwang Sik Kim, Sharon Nachman, Marian D Pfefferkorn, Timothy Sentongo, Janice E Sullivan, Pamela Sears. Safety and Pharmacokinetic Study of Fidaxomicin in Children With Clostridium difficile-Associated Diarrhea: A Phase 2a Multicenter Clinical Trial. Journal of the Pediatric Infectious Diseases Society. 2018 Aug; 7(3):210-218. doi: 10.1093/jpids/pix037. [PMID: 28575523]
  • N J Ajami, J L Cope, M C Wong, J F Petrosino, L Chesnel. Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice. Antimicrobial agents and chemotherapy. 2018 05; 62(5):. doi: 10.1128/aac.02112-17. [PMID: 29463537]
  • Laura J Baumgartner, Lauren Brown, Curt Geier. Hypersensitivity Reaction Following Administration of Low-Dose Oral Vancomycin for the Treatment of Clostridium difficile in a Patient With Normal Renal Function. Journal of pharmacy practice. 2017 Dec; 30(6):650-652. doi: 10.1177/0897190016668437. [PMID: 27630210]
  • C Fehér, E Múñez Rubio, P Merino Amador, A Delgado-Iribarren Garcia-Campero, M Salavert, E Merino, E Maseda Garrido, V Díaz-Brito, M J Álvarez, J Mensa. The efficacy of fidaxomicin in the treatment of Clostridium difficile infection in a real-world clinical setting: a Spanish multi-centre retrospective cohort. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2017 Feb; 36(2):295-303. doi: 10.1007/s10096-016-2802-x. [PMID: 27718071]
  • Abhishek Deshpande, Kelly Hurless, Jennifer L Cadnum, Laurent Chesnel, Lihong Gao, Luisa Chan, Sirisha Kundrapu, Alexander Polinkovsky, Curtis J Donskey. Effect of Fidaxomicin versus Vancomycin on Susceptibility to Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice. Antimicrobial agents and chemotherapy. 2016 07; 60(7):3988-93. doi: 10.1128/aac.02590-15. [PMID: 27090175]
  • Abrar K Thabit, M Jahangir Alam, Mohammed Khaleduzzaman, Kevin W Garey, David P Nicolau. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin. Annals of clinical microbiology and antimicrobials. 2016 Apr; 15(?):22. doi: 10.1186/s12941-016-0140-6. [PMID: 27071986]
  • Seth T Housman, Abrar K Thabit, Joseph L Kuti, Richard Quintiliani, David P Nicolau. Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin. Infection control and hospital epidemiology. 2016 Feb; 37(2):215-8. doi: 10.1017/ice.2015.270. [PMID: 26592763]
  • Caroline H Chilton, Grace S Crowther, Helen Ashwin, Chris M Longshaw, Mark H Wilcox. Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin Production. PloS one. 2016; 11(8):e0161200. doi: 10.1371/journal.pone.0161200. [PMID: 27556739]
  • Jason C Gallagher, Joseph P Reilly, Bhagyashri Navalkele, Gemma Downham, Kevin Haynes, Manish Trivedi. Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection. Antimicrobial agents and chemotherapy. 2015 Nov; 59(11):7007-10. doi: 10.1128/aac.00939-15. [PMID: 26324268]
  • C Rubio-Terrés, J Cobo Reinoso, S Grau Cerrato, J Mensa Pueyo, M Salavert Lletí, A Toledo, P Anguita, D Rubio-Rodríguez, M Watt, R Gani. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2015 Nov; 34(11):2213-23. doi: 10.1007/s10096-015-2472-0. [PMID: 26407619]
  • C H Chilton, G S Crowther, S L Todhunter, H Ashwin, C M Longshaw, A Karas, M H Wilcox. Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model. The Journal of antimicrobial chemotherapy. 2015 Sep; 70(9):2598-607. doi: 10.1093/jac/dkv156. [PMID: 26078392]
  • Hiroyuki Oshima, Takao Yamazaki, Lauren Benner, Takashi Miki, Ingrid Michon, Tomasz Wojtkowski, Atsunori Kaibara, Salim Mujais. Comparison of the safety, tolerability, and pharmacokinetics of fidaxomicin in healthy Japanese and caucasian subjects. Clinical drug investigation. 2015 Jun; 35(6):375-84. doi: 10.1007/s40261-015-0291-9. [PMID: 25972286]
  • Neil Stollman, Mark Smith, Andrea Giovanelli, Gina Mendolia, Laura Burns, Eliska Didyk, James Burgess, Andrew Noh, Carolyn Edelstein, Eric Alm, Zain Kassam. Frozen encapsulated stool in recurrent Clostridium difficile: exploring the role of pills in the treatment hierarchy of fecal microbiota transplant nonresponders. The American journal of gastroenterology. 2015 Apr; 110(4):600-1. doi: 10.1038/ajg.2015.81. [PMID: 25853204]
  • Abdul Sattar, Pia Thommes, Lloyd Payne, Peter Warn, Richard J Vickers. SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI. The Journal of antimicrobial chemotherapy. 2015; 70(6):1757-62. doi: 10.1093/jac/dkv005. [PMID: 25652749]
  • J J Keller, E J Kuijper. Treatment of recurrent and severe Clostridium difficile infection. Annual review of medicine. 2015; 66(?):373-86. doi: 10.1146/annurev-med-070813-114317. [PMID: 25587656]
  • S Weis, E John, N Lippmann, J Mössner, C Lübbert. [Clostridium difficile infection (CDI) in the course of time - an issue only for the internist?]. Zentralblatt fur Chirurgie. 2014 Aug; 139(4):460-8. doi: 10.1055/s-0032-1328623. [PMID: 24132675]
  • Marta Piekarska, Alicja D Wandałowicz, Henryka Miigoć. [Clostridium difficile infecion--diagnostics, prevention and treatment]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego. 2014 Apr; 36(214):278-82. doi: . [PMID: 24868904]
  • Lisa N Patel, Jason Schairer, Bo Shen. Fecal transplantation therapy for Clostridium difficile-associated pouchitis. International journal of colorectal disease. 2014 Feb; 29(2):263-4. doi: 10.1007/s00384-013-1771-0. [PMID: 24132529]
  • Dominik Cieniawski, Ewa Ignacak, Alina Bętkowska-Prokop, Barbara Dudzik, Bogusław Walatek, Marek Kuźniewski, Władysław Sułowicz. [Reccurent Clostridium difficile infection in patient after kidney transplantation on rituximab therapy due to PTLD (Post-Transplant Lymphoprolipherative Disorder). First experience with Fidaxomicin use--case report]. Przeglad lekarski. 2014; 71(12):724-7. doi: NULL. [PMID: 25951705]
  • A Ebigbo, H Messmann. [Challenges of Clostridium difficile infection]. Medizinische Klinik, Intensivmedizin und Notfallmedizin. 2013 Nov; 108(8):624-7. doi: 10.1007/s00063-013-0258-7. [PMID: 24129852]
  • C Monneret. [Four new drugs on the market: abiraterone, belatacept, vandetanib and fidaxomycine]. Annales pharmaceutiques francaises. 2013 Mar; 71(2):95-103. doi: 10.1016/j.pharma.2013.01.004. [PMID: 23537410]
  • Cirle A Warren, Edward J van Opstal, Mary S Riggins, Yuesheng Li, John H Moore, Glynis L Kolling, Richard L Guerrant, Paul S Hoffman. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. Antimicrobial agents and chemotherapy. 2013 Feb; 57(2):689-96. doi: 10.1128/aac.00877-12. [PMID: 23147742]
  • Susan M Pacheco, Stuart Johnson. Important clinical advances in the understanding of Clostridium difficile infection. Current opinion in gastroenterology. 2013 Jan; 29(1):42-8. doi: 10.1097/mog.0b013e32835a68d4. [PMID: 23207596]
  • Els van Nood, Josbert J Keller, Ed J Kuijper, Peter Speelman. [New treatment options for infections with Clostridium difficile]. Nederlands tijdschrift voor geneeskunde. 2013; 157(48):A6580. doi: NULL. [PMID: 24279951]
  • Kathleen M Mullane, Oliver A Cornely, Derrick W Crook, Yoav Golan, Thomas J Louie, Mark A Miller, Michelle A Josephson, Sherwood L Gorbach. Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. American journal of nephrology. 2013; 38(1):1-11. doi: 10.1159/000351757. [PMID: 23796582]
  • Pamela Sears, Derrick W Crook, Thomas J Louie, Mark A Miller, Karl Weiss. Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2012 Aug; 55 Suppl 2(?):S116-20. doi: 10.1093/cid/cis337. [PMID: 22752859]
  • Iris Figueroa, Stuart Johnson, Susan P Sambol, Ellie J C Goldstein, Diane M Citron, Dale N Gerding. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2012 Aug; 55 Suppl 2(?):S104-9. doi: 10.1093/cid/cis357. [PMID: 22752857]
  • Derrick W Crook, A Sarah Walker, Yin Kean, Karl Weiss, Oliver A Cornely, Mark A Miller, Roberto Esposito, Thomas J Louie, Nicole E Stoesser, Bernadette C Young, Brian J Angus, Sherwood L Gorbach, Timothy E A Peto. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2012 Aug; 55 Suppl 2(?):S93-103. doi: 10.1093/cid/cis499. [PMID: 22752871]
  • Oliver A Cornely, Mark A Miller, Thomas J Louie, Derrick W Crook, Sherwood L Gorbach. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2012 Aug; 55 Suppl 2(?):S154-61. doi: 10.1093/cid/cis462. [PMID: 22752865]
  • Ellie J C Goldstein, Farah Babakhani, Diane M Citron. Antimicrobial activities of fidaxomicin. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2012 Aug; 55 Suppl 2(?):S143-8. doi: 10.1093/cid/cis339. [PMID: 22752863]
  • Thomas J Louie, Kris Cannon, Brendan Byrne, Judy Emery, Linda Ward, Melissa Eyben, Walter Krulicki. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2012 Aug; 55 Suppl 2(?):S132-42. doi: 10.1093/cid/cis338. [PMID: 22752862]
  • Michelle M Nerandzic, Kathleen Mullane, Mark A Miller, Farah Babakhani, Curtis J Donskey. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2012 Aug; 55 Suppl 2(?):S121-6. doi: 10.1093/cid/cis440. [PMID: 22752860]
  • Oliver A Cornely, Derrick W Crook, Roberto Esposito, André Poirier, Michael S Somero, Karl Weiss, Pamela Sears, Sherwood Gorbach. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. The Lancet. Infectious diseases. 2012 Apr; 12(4):281-9. doi: 10.1016/s1473-3099(11)70374-7. [PMID: 22321770]
  • Thomas J Louie, Mark A Miller, Kathleen M Mullane, Karl Weiss, Arnold Lentnek, Yoav Golan, Sherwood Gorbach, Pamela Sears, Youe-Kong Shue. Fidaxomicin versus vancomycin for Clostridium difficile infection. The New England journal of medicine. 2011 Feb; 364(5):422-31. doi: 10.1056/nejmoa0910812. [PMID: 21288078]
  • Gerald W Tannock, Karen Munro, Corinda Taylor, Blair Lawley, Wayne Young, Brendan Byrne, Judy Emery, Thomas Louie. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology (Reading, England). 2010 Nov; 156(Pt 11):3354-3359. doi: 10.1099/mic.0.042010-0. [PMID: 20724385]
  • Wen Qiang Chen, Lin Zhong, Lei Zhang, Xiao Ping Ji, Yu Xia Zhao, Cheng Zhang, Hong Jiang, Yi Ling Wu, Yun Zhang. Chinese medicine tongxinluo significantly lowers serum lipid levels and stabilizes vulnerable plaques in a rabbit model. Journal of ethnopharmacology. 2009 Jul; 124(1):103-10. doi: 10.1016/j.jep.2009.04.009. [PMID: 19527824]
  • Yevgen O Posokhov, Mykola V Rodnin, Lucy Lu, Alexey S Ladokhin. Membrane insertion pathway of annexin B12: thermodynamic and kinetic characterization by fluorescence correlation spectroscopy and fluorescence quenching. Biochemistry. 2008 May; 47(18):5078-87. doi: 10.1021/bi702223c. [PMID: 18407663]
  • R N Swanson, D J Hardy, N L Shipkowitz, C W Hanson, N C Ramer, P B Fernandes, J J Clement. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrobial agents and chemotherapy. 1991 Jun; 35(6):1108-11. doi: 10.1128/aac.35.6.1108. [PMID: 1929250]